


AMENDMENTS

Kindly amend the application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula:



wherein:

P is a water soluble polymer;

m is an integer of ~~2~12~~ from 2-12 inclusive;

j is an integer of ~~1~6~~ from 1-6 inclusive;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

2. (Currently amended) The conjugate of claim 1, wherein the water soluble polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyacrylmorpholine and copolymers thereof.


3. (Currently amended) The conjugate of claim 2, wherein the water soluble polymer is polyethylene glycol.

4. (Currently amended) The conjugate of claim 3, wherein the molecular weight of polyethylene glycol is ~~300-60,000~~ from 300 to 60,000.

5. (Currently Amended) The conjugate of claim 1, wherein the linking group X is selected from the group consisting of $(CH_2)_i$, $(CH_2)_iOCO$, $(CH_2)_iNHCO$ [[or]] and $(CH_2)_iCO$, and ~~wherein~~ wherein i is an integer ~~of 0-10~~ from 0-10, inclusive.

6. (Currently amended) The conjugate of claim 1, wherein ~~[[the]]~~ a free hydroxyl on the hydrophilic polymer can be substituted by C_{1-12} alkoxy, cycloalkoxy or aroxy.

7. (Currently Amended) The conjugate of claim 1, wherein ~~[[the]]~~ a free hydroxyl on the hydrophilic polymer ~~[[can be]]~~ is substituted by the following formula:



~~Wherein: x, m, j, R_i, Z and TA are the same as defined in claim 1.~~

wherein:

P is a water soluble polymer;

m is an integer from 2-12 inclusive;

j is an integer from 1-6 inclusive;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

8. (Currently amended) The conjugate of claim 1, wherein target molecule can be carried in the hydrophilic polymer to perform targeted delivery of the conjugate.

9. (Currently amended) The conjugate of claim 8, wherein the target molecule is an antibody.

10. (Currently Amended) The conjugate of claim 1, wherein the drug ~~[[part]]~~ molecule TA is ~~any one~~ selected from the group consisting of amino acids, proteins, enzymes, nucleosides, saccharides, organic acids, glycosides, flavonoids, quinones, terpenoids, phenylpropanoid phenols, steroids and glycosides thereof and alkaloids.


11. (Currently amended) The conjugate of claim 10, wherein the drug ~~moiety~~ molecule TA is ~~[[the]]~~ an active ingredient of a nature medicine.

12. (Currently amended) The conjugate of claim 11, wherein the ~~natural~~ active ingredient is cinobufagin, clycyrrhetic acid or scopoletin.

13. (Currently amended) The conjugate of claim 10, wherein the drug ~~moiety~~ molecule TA is an antitumor agent.

14. (Currently amended) The conjugate of claim 13, wherein the antitumor agent is selected from the group consisting of paclitaxel, camptothecin, hydroxycamptothecin, etoposide and derivatives thereof.

15. (Currently Amended) A conjugate of methoxypolyethylene glycol-glutamic acid oligopeptide and drug molecule having the following formula:



wherein:

n is an integer ~~of 10-1200~~ from 10-1200;

m is an integer ~~of 2-12~~ from 2-12;

X is a linking group selected from the group consisting of $(\text{CH}_2)_i$, $(\text{CH}_2)_i\text{OCO}$, $(\text{CH}_2)_i\text{NHCO}$ and $(\text{CH}_2)_i\text{CO}$, and wherein i is an integer ~~of 0-10~~ from 0-10 inclusive;

Z is a linking group selected from O and NH; and

PT is a drug molecule selected from the group consisting of paclitaxel, camptothecin, cinobufagin, clycyrrhethinic acid, scopoletin and derivatives thereof.

Application Serial No.: 10/506,524

16. (Currently Amended) A composition comprising a conjugate according to ~~any one of claims~~ claim 1 to 15 and a pharmaceutically acceptable carrier or excipient.

17. (Currently amended) The composition of claim 16, further comprising another therapeutically active ingredient.

18. (Currently amended) The composition of claim 16, wherein ~~it may be the composition is~~ formulated into ~~[[the]]~~ a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, ~~[[and]]~~ a hard gelatin capsule~~[[s]]~~, a powder, a solution, a suspension, ~~[[or]]~~ and an aerosol.

19. (Canceled)

Please add the following new claims:

20. (New) A composition comprising a conjugate according to claim 15 and a pharmaceutically acceptable carrier or excipient.

21. (New) The composition of claim 20, further comprising another therapeutically active ingredient.

22. (New) The composition of claim 20, wherein the composition is formulated into a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, a hard gelatin capsule, a powder, a solution, a suspension, and an aerosol.